retatrutide grey market price Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide isn't supposed to be

That is not a safe medical practice

Retatrutide is a next-generation triple agonist peptide targeting the GIP (glucose-dependent insulinotropic polypeptide) , GLP-1 (glucagon-like peptide-1) , and glucagon receptors

Better insulin management directly supports sustained weight loss and combats insulin resistance, frequently associated with obesity

You deserve a program that supports your whole healthnot just your weight

Time zones can make your injection timing confusing

Retatrutide (also known as LY-3437943) is an experimental medication developed by Eli Lilly that is being studied as a next-generation treatment for obesity, overweight, and related metabolic conditions such as type 2 diabetes